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Use of Mediation to  
Recover Rights to Our Genes 
Rachel Albert* 
I.  INTRODUCTION 
We live in an era of technology and innovation.  Yet the controversial 
nature of patents on genes that correlate with human disease has been 
undisputed since patents were first granted.1  Scientists have made a lot of 
progress since the late 1970s.  They have developed new strains of plants 
capable of producing higher yields and resisting viruses, as well as created 
“transgenic” animals that can produce an array of human pharmaceutical 
compounds.2  These compounds would otherwise be unavailable because of 
the high expense of insufficient sources of supply.3  Research of genetic 
materials has also allowed scientists to study the cause of human diseases 
and target the specific gene sequence that creates the defect. 
Patent protection attempts to strike a balance between giving both 
protection and incentives that lead to inventor creation and the public 
interest in preventing barriers to the flow of information that might permit 
invention.4  Public controversy has centered on the contextual aspects of 
diagnosing disease through the use of patents that are granted to individuals 
who discovered disease-associated genes.5  However, arbitration can be 
 
*  Juris Doctor Candidate 2016, Pepperdine University School of Law. 
 1. Robert Cook-Deegan & Annie Niehaus, After Myriad: Genetic Testing in the Wake of 
Recent Supreme Court Decisions About Gene Patents, NCBI (Sept. 11, 2014), 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225052/.  
 2. MARTIN ADELMAN ET AL., CASES AND MATERIALS ON PATENT LAW 67 (4th ed. 2015). 
 3. Id. 
 4. Id.  
 5. Two scholars have noted: 
Policy reports on “gene patents” began to appear in the early mid-1990s, an indicator of 
emerging policy conflict.  The discovery of genetic changes associated with Huntington’s 
diseases, Duchenne[,] and Becker muscular dystrophy, cystic fibrosis, neurofibromatosis, 
Alzheimer’s disease and other conditions led to DNA-based diagnostic methods to 
identify those at high-inherited risk in families with apparent Mendelian inheritance 
patterns.    
Cook-Deegan & Niehaus, supra note 1.   
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better utilized to solve conflicts with patented inventions.  This paper will 
address the way that gene patents present a special issue in arbitration. 
Within the specialized body of law commonly referred to as intellectual 
property (IP), federal courts are authorized to protect property that fall under 
the following categories of creations of the mind: inventions, literary works, 
artistic works, designs, symbols, names, and images used in commerce.6  
The multiple subcategories of IP are protected with laws that govern the 
legal instruments that are dedicated to each subcategory, which are patents, 
copyrights, and trademarks.7  These different instruments facilitate the 
inventors to earn recognition and wealth from the IP that they create.8 
Therefore, it is easy to see how there needs to be a correct balance between 
the credit that is due to innovators and also the interest and ability for the 
public to use the inventions for the public welfare.9  Thus, the IP system 
strives to allow innovation and creativity to flourish while also protecting 
innovator’s rights.  A specific concern of inventors is the constrained time 
frame that is desired.10  If this time frame is elongated unnecessarily, then 
the proceedings can be harmful to the inventor’s rights because technology 
tends to evolve quickly and can render a pending invention obsolete.11  
These dragged out proceedings can interfere with a business’s development 
plans.12  For instance, if a company came up with a new product but is 
unsure of how the patent litigation will be decided, it may be forced to end 
product production until it is ultimately determined by the court Patent 
licensing disputes are not typically resolved in arbitration or mediation, but 
they can serve as preferable methods for resolving the patent process. 
License disputes often arise when a patent owner (or licensor) licenses 
gene patents to a licensee who later disputes that royalties are due because 
the patent does not cover what the licensee is doing, or because the patent is 
invalid.13  Recently, the Patent Office granted a substantial number of 
patents on genetic sequences that may not be valid pursuant to the 2013 
Supreme Court decision in Association of Molecular Pathology v. Myriad 
 
 6. What is Intellectual Property?, WIPO, http://www.wipo.int/about-ip/en/ (last visited Feb. 
23, 2016).  
 7. Id. 
 8. Id. 
 9. Id. 
 10. See Craig Metcalf, Resolution of Patent and Technology Disputes by Arbitration and 
Mediation: A View from the United States, 74 ARB: J. CHARTERED INST. ARBS. 385, 385 (2008), 
http://www.kmclaw.com/media/article/1_metcalf-arbitration%20article.pdf. 
 11. Id. 
 12. Id. 
 13. See D. Brian Kacedon et al., Licensee May Challenge Patent Validity and Infringement in 
Royalty Disputes When Royalties are Tied to the Practice of Licensed Patents, FINNEGAN (May 26, 
2015), http://www.finnegan.com/resources/articles/articlesdetail.aspx?news=b27728c0-34d1-4162-
9fd0-40298591522e. 
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Genetics,14 which held that naturally occurring DNA segments associated 
with ovarian and breast cancer claimed by Myriad were not patentable under 
35 U.S.C. § 101.15  There, the Court was less than clear when it ruled that 
isolated DNA in a particular sequence found in nature is not patent-eligible, 
but that synthetic DNA can be patented because it is not naturally 
occurring.16  Thus, patents can be granted to those who invent something 
new and useful, but not for simple discovery of the location of a gene.  
However, the Court did not address the patentability of DNA with 
nucleotides that have been altered.17  One may wonder if patents can be 
issued for sequences that have only been slightly altered. 
II.  SIGNIFICANCE OF THE TOPIC 
By 2011, the United States Patent and Trademark Office (USPTO) had 
issued over 2,500 patents claiming isolated DNA.18  In addition, the USPTO 
issued 40,000 patents that were related to human genes existing in forms 
other than their native form.19  Patents involving gene sequences will 
undoubtedly have implications in the future involving different types of 
genetic testing, agriculture, and gene therapy.  For instance, if an artificial 
gene can be used to treat an illness, and if the artificial gene can be patented, 
it can prevent competition and make treatment more expensive for members 
of the public that need it.20  Furthermore, the person who holds the patent 
can hold a monopoly over the patented material and licensing fees can often 
be extremely costly.21  It can also prevent further research on that specific 
gene because anyone seeking to use the patented gene would need a 
 
 14. Ass’n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107, 2120 (2013). 
 15. Id.  Section 101 of the Patent Act describes the subject matter that can be patented.  35 
U.S.C. § 101 (2015).  To be eligible to receive a utility patent, the invention must fall into one of the 
four categories—processes, machines, manufactures, and compositions of matter—and must also 
meet the other requirements of the Patent Act. 35 U.S.C. § 101.  The Supreme Court has long held 
that there are certain exceptions to this provision: laws of nature, natural phenomena, and abstract 
ideas.  Alice Corp. v. CLS Bank Int’l, 134 S. Ct. 2347, 2354 (2014). 
 16. Myriad, 134 S. Ct. at 2354.  In Myriad, the Supreme Court affirmed in part and reversed in 
part the decision of the Unites States Court of Appeals for the Federal Circuit.  Id. at 2107. 
 17. Id. 
 18. Charles R. Macedo et al., Isolated Human Genes and Related Therapeutic Treatment 
Methods Held Patent-eligible, 8 J. INTELL. PROP. L. & PRAC. 96, 96 (2013), 
http://jiplp.oxfordjournals.org/content/8/2/96.abstract. 
 19. Id. 
 20. Id. 
 21. Sapna Kumar, Life, Liberty, and the Pursuit of Genetic Information, 65 ALA. L. REV. 625, 
648 (2014). 
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license.22  Even with the Myriad decision, labs may face issues where 
cDNA, or synthetic DNA, is patented and they do not hold the patent.23  
Complementary DNA, cDNA,24 is often used as a starting point for cloning 
eukaryotic genes, and gene libraries that include only genes transcribed in a 
particular tissue at a particular time can be made from complementary 
DNA.25  Synthesis of cDNA is especially useful for identifying mRNAs that 
are present only in a few copies.26 
In some instances, even if they wish to be a licensee, they may not be 
able to get a license, and if parties go to court, litigation may take years.27  
Especially where health concerns can be pressing i.e. with cancer testing (the 
Myriad decision), two years might make a real difference to a cancer patient 
seeking to benefit from additional research on diagnostics with the BRCA 
genes.  Arbitration can thus be useful for its shorter time span but also can 
give the added benefit of utilizing experts who actually have science 
backgrounds.28  However, would an increased emphasis on arbitration harm 
consumers?  It may indeed harm consumers because it can keep the specific 
reasons for the decision unrevealed and confidential.29  This confidentiality 
would prevent other parties from quickly learning about the invalid patent 
and pursuing further research, but those who do arbitrate can be rewarded in 
the sense that they can reach a faster result and even get a head start on 
research and development. 
Also, reducing the cost of trial might reduce the cost of the patent, since 
the parties involved in the arbitration dispute may factor in litigation 
expenses where licensing agreements are involved.  Thus, arbitration might 
be a more efficient and useful solution.  As an alternative to arbitration, 
mediation would be feasibly utilized to diffuse a potentially hostile dispute 
that could entail a harmful and longwinded litigation.  Mediation could 
transform this type of dispute with a more docile mode of resolution that 
 
 22. See id. 
 23. See Ass’n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107 (2013). 
 24. Complementary DNA is synthesized by combining an mRNA template with a 3’ poly A 
tail with reverse transcriptase enzyme.  A short oligo dT primer is added and allowed to hybridize 
with the poly A tail.  Reverse transcriptase synthesizes cDNA using the mRNA template, creating a 
DNA-RNA hybrid.  When synthesis is completed, the mRNA is removed, leaving single-stranded 
cDNA.  DNA polymerase uses the cDNA as a template to make a complementary DNA strand.  
WILLIAM K. PURVES ET AL., LIFE: THE SCIENCE OF BIOLOGY 326 (7th ed. 2004). 
 25. Id. 
 26. Id. 
 27. Richard H. Sayler, The Case for Arbitrating Intellectual Property Licensing Disputes, 60 
DISP. RESOL. J. 62, 62-65 (2005), https://www.adr.org/aaa/ShowPDF?doc=ADRSTG_012013. 
 28. Id.  
 29. See Canon VII of the AAA Code of Ethics (requiring arbitrators to maintain 
confidentiality).  But see Laura A. Kaster, Confidentiality in U.S. Arbitration, APPROPRIATED DISP. 
RESOL. (Spring 2012), http://appropriatedisputesolutions.com/site/wp-
content/uploads/2013/01/Confidentiality-”DRS-NewsSpr12.pdf”.pdf.  
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meets the goals of both parties and bolsters the product’s ability to serve 
both the creator and the public consumer.30 
III.  BACKGROUND 
It is likely true that, without patent protection, “the biotechnology 
research that lies at the heart of these discovered [patents] might never have 
occurred.”31  Some researchers also believe that “exclusive licensing of gene 
patents has reduced the availability of genetic testing to patients.”32  
However, due to the landmark Supreme Court decision in Myriad, many of 
the previously granted gene sequence patents are now invalid.33  When the 
Supreme Court makes decisions such as Myriad,34 where gene patents are 
later found to be invalid, the gene patent invalidity issue can significantly 
impact arbitrations involving gene patent licenses.  In such cases, the 
licensee can argue it is not liable to pay license fees because the gene patent 
is invalid.  If the arbitrator agrees, the licensee does not have to pay the 
license fee.  However, if the arbitration is private,35 other licensees of the 
same patent will not necessarily know the result.  On the other hand, if a 
licensee challenges the validity of a gene patent in court, and the court finds 
the patent to be invalid, this has collateral estoppel impact and releases all 
licensees from payment of license fees.36  Collateral estoppel occurs when a 
judgment in one court action serves as a bar in a later action to the re-
litigation of issues that were actually litigated and conclusively adjudicated 
in the first action.37 
It would be favorable for a gene patent owner to want a patent dispute to 
be resolved by alternative means that allow for confidentiality so that other 
 
 30. Dispute Resolution for SMEs, WIPO ARB. & MEDIATION CTR. 1, http://www.wipo.int/ 
export/sites/www/sme/en/documents/pdf/arbitration_mediation.pdf (last visited Feb. 25, 2015). 
 31. Jennifer Vogel, Patenting DNA: Balancing the Need to Incentivize Innovation in 
Biotechnology with the Need to Make High-Quality Genetic Testing Accessible to Patients, 61 U. 
KAN. L. REV. 257, 292-93 (2012). 
 32. Kumar, supra note 21, at 648. 
 33. Christopher Bergin, Take Off Your Genes and Let the Doctor Have A Look: Why the Mayo 
and Myriad Decisions Have Invalidated Method Claims for Genetic Diagnostic Testing, 63 AM. U. 
L. REV. 173, 209 (2013). 
 34. Ass’n of Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107, 2120 (2013) 
 35. See Canon VII of the AAA Code of Ethics, which requires arbitrators to maintain 
confidentiality.  But see Richard C. Reuben, Confidentiality in Arbitration: Beyond the Myth, 54 U. 
KAN. L. REV. 1255, 1256 (2006) (discussing the difference between confidentiality and privacy in 
arbitration).  
 36. See Blonder-Tongue Labs. v. Univ. of Ill. Found., 402 U.S. 313 (1971). 
 37. See Collateral Estoppel, PRAC. L. (2016), http://us.practicallaw.com/5-518-6335.  
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licensees are not aware of the outcome.  Likewise, the patent challenger 
often wants to avoid paying the licensing fee, but would also want to prevent 
the rest of the market from violating the patent because they would not want 
to draw attention to the fact that it is not a valid patent since, consequently, if 
other competitors were aware, there would be more competition in the 
market.  Thus, both licensor and licensee may potentially favor arbitration 
over litigation, and arbitration would likely make both parties to a patent 
licensing dispute more content with the results instead of resorting to 
litigation.  Arbitration can also occur much more quickly than litigation, 
allowing research to continue more quickly than if parties waited for an 
outcome from litigation.38  This can have a significant impact in the medical 
field, where human lives are at stake. 
Patent disputes resolved through litigation cannot typically be re-
litigated, even if a party with an interest at stake was not initially present in 
the suit.39  In Blonder-Tongue v. University of Illinois Foundation,40 the 
Court set forth the rule that once a patent has been declared invalid via 
judicial inquiry, a collateral estoppel barrier is created against further 
litigation involving the patent, unless the patentee-plaintiff can demonstrate 
that they did not have a fair chance to litigate the validity of his patent in an 
earlier case.41 
Despite this ruling, in Lear, Inc. v. Adkins, the Supreme Court 
overturned the doctrine of licensee estoppel and held that licensees are free 
to challenge the validity of a spurious patent under which they are licensed 
even if a contract entered into among the parties states that he could not 
challenge it, and thus, the licensee was permitted to refrain from paying 
patent royalties if the patent he held a license to was deemed invalid, even if 
the parties had made an agreement not to challenge its validity.42 
According to the American Arbitration Association, arbitration is a tool 
that is approved for the resolution for licensing and IP disputes.43  
Specifically, arbitration can resolve disputes involving patents, trademarks, 
and copyrights.44  In these types of disputes, arbitration has proven to be 
more advantageous than litigation in terms of the following categories: 
 
 38. Barbara Kate Repa, Arbitration Pros and Cons, NOLO, http://www.nolo.com/legal-
encyclopedia/arbitration-pros-cons-29807.html (last visited Feb. 20, 2016). 
 39. See Blonder-Tongue Labs. v. Univ. of Ill. Found., 402 U.S. 313 (1971). 
 40. Id. 
 41. Id. 
 42. Lear, Inc. v. Adkins, 395 U.S. 653, 675-76 (1969). 
 43. Intellectual Property/Licensing, AM. ARB. ASS’N (2014), https://www.adr.org/aaa/faces/ 
aoe/commercial/intellectualpropertylicensing?_afrLoop=891677053851491&_afrWindowMode=0&
_afrWindowId=1bp2y79lfx_203#%40%3F_afrWindowId%3D1bp2y79lfx_203%26_afrLoop%3D89
1677053851491%26_afrWindowMode%3D0%26_adf.ctrl-state%3D1bp2y79lfx_227 (last visited 
Feb. 20, 2016).  
 44. Id. 
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• speed and economy; 
• privacy; 
• reduced likelihood of damage to ongoing business relationships; 
• ease of enforcement in the international context; and 
• ability of the parties to customize the process and select arbitrators 
who are experts familiar with the subject matter of the underlying 
dispute.45 
 
In order to properly facilitate arbitration in the IP law arena, the 
American Arbitration Association provides panels of neutral arbitrators that 
have expertise in the following areas of IP: patents, trademarks, copyrights, 
licensing, technology, biotechnology, and pharmaceuticals.46  This 
particularized expertise provides another great advantage over litigation, 
where judges and jury-members typically have very limited scientific 
knowledge. 
IV.  RIGHTS OF AN OWNER 
The patent owner is granted the exclusive right to prevent others from 
making, using, offering for sale, or selling the patented invention.47  Under 
35 U.S.C. § 154 (2015), current statutory provisions, the term of protection 
for utility patents is twenty years measured from the date of filing48 with 
extensions of up to five years permitted for drugs, medical devices, and 
additives.49  Also, under 35 U.S.C. § 173 (2015), the current term of 
protection for design patents is fifteen years from the date of filing.50  The 
exhaustion doctrine, which is a longstanding doctrine of patent law, entitles 
a patentee to a single royalty per patented device and the rule prevents 
patentees from collecting a series of royalties for a single invention.51  Thus, 
the exhaustion doctrine prevents a patentee from bringing an action against a 
 
 45. Id. 
 46. Id. 
 47. See 35 U.S.C. § 154 (2015). 
 48. Id. § 154(a)(2). 
 49. Id. § 156. 
 50. See id. § 173.  
 51. Erin Julia Daida Austin, Reconciling the Patent Exhaustion and Conditional Sale 
Doctrines in Light of Quanta Computer v. LG Electronics, 30 CARDOZO L. REV. 2947, 2947-49 
(2009). 
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third party purchaser after having already received a royalty payment from 
the initial sale.52 
V.  PATENT ARBITRATION 
The Patent Act at 35 U.S.C. § 294(a) provides that any arbitration clause 
contained in a patent agreement shall be presumed valid, irrevocable, and 
enforceable.53  Also, the Supreme Court has described the Federal 
Arbitration Act54 as evidence of a “national policy favoring arbitration.”55  
Even still, as IP attorney Chris Neumeyer explains, the number of disputes 
in Patent law that undergo arbitration is small.56  Additionally, 
internationally, the number is even fewer.57  In contrast, Neumeyer notes that 
in 2012 the number of patent-related lawsuits increased to more than 
5,000.58  These 5,000 lawsuits were all filed in U.S. District Courts.  Several 
well-known companies have in recent years resorted to arbitration.59  The 
recent trend began in 2012 when both Research in Motion and Nokia 
successfully underwent arbitration in regards to a licensing dispute.60  This 
occurred in a Swedish tribunal that awarded Nokia royalties because RIM 
infringed standard-essential patents (SEPs) that were owned by Nokia.61  In 
2013 Google proposed that Apple use arbitration to resolve a dispute that 
concerned particular patents.62  In this particular dispute, however, the 
parties did not reach an agreement.63  In that same year, there was an 
announcement that Tessera Technologies was owed $130 million in royalties 
 
 52. Southland Corp. v. Keating, 465 U.S. 1, 10 (1984); see Quanta Comput. v. LG Elecs., 553 
U.S. 617 (2008).  
 53. Buckeye Check Cashing v. Cardegna, 546 U.S. 440, 443 (2006); See 35 U.S.C. § 294(a) 
(2012). 
 54. 9 U.S.C. § 1 (2015). 
 55. Southland, 465 U.S. at 10; Nitro-Lift Techs. v. Howard, 133 S. Ct. 500, 501 (2012) (per 
curiam). 
 56. Chris Neumeyer, Think Patent Arbitration Can’t Work? Think Again, IPWATCHDOG (June 
10, 2013), http://www.ipwatchdog.com/2013/06/10/think-patent-arbitration-cant-work-think-
again/id=41447/; see also About Chris Neumeyer, INT’L TECH. L. BLOG, 
http://techlaw.biz/author/admin/ (last visited Mar. 3, 2016). 
 57. Id. 
 58. Id. 
 59. See id. (discussing well-known companies such as Google, Apple, and Genetech). 
 60. Id.; Nokia Corp. v. Research in Motion Ltd., 2012 U.S. Dist. LEXIS 174761 (N.D. Cal. 
Dec. 7, 2012) 
 61. Neumeyer, supra note 56.  
 62. Id. 
 63. Id. 
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plus $64 million in royalties as per both a patent licensing agreement and an 
order that had been previously awarded from an earlier arbitration.64 
By choosing arbitration, parties are able to facilitate savings in multiple 
ways.  Neumeyer notes some of the following methods: to limit the amount 
of arbitrators, to restrict the scope of discovery, to submit to the pleadings, to 
prevent the review of a final award, and to impose limits on motions.65  
Also, arbitration can provide for a significant amount of savings in patent 
disputes that span across multiple jurisdictions by facilitating a single 
agreement that allows the possibility of halting inter-jurisdictional 
litigation.66  Arbitration also allows for flexibility, which is essential because 
agreement on various logistical issues creates a smoother process.  Such 
logistical issues include: the location for arbitration, the qualifications of 
arbitrators, access to interim relief, governing law, procedural rules, 
language, evidence, and timing.67  Thus, arbitration allows parties to avoid 
litigation where forums may be biased or where judges or juries are ignorant 
about essential knowledge of the relevant field.  To the contrary, the parties 
are instilled with the power to select arbitrators who are experts, neutral, and 
specialized.68  The International Chamber of Commerce has established a 
working roster of professional arbitrators that hold the specialized 
credentials of engineers and patent lawyers.69 
There are certain situations, however, where arbitration does not provide 
a resolution to patent disputes across multiple countries.70  Even still, there 
are variations in the way different courts reserve the right to arbitrate 
disputes.  In the United States, courts can arbitrate disputes regarding patent 
infringement.71  However, that is not the case in China and Japan.72  If 
jurisdictions deny the ability for arbitration to govern patent disputes, then it 
is highly possible that local courts may deny enforcement of awards issued 
in another country.73  There are fewer grounds that are used to overturn 
 
 64. Tessera Wins Key Ruling in Arbitration Versus Amkor, TESSERA (Feb. 20, 2013), 
http://ir.tessera.com/releasedetail.cfm?ReleaseID=741970. 
 65. Neumeyer, supra note 56. 
 66. Id. 
 67. Id. 
 68. Id. 
 69. Id.; see also Arbitration and ADR, INT’L CHAMBER OF COM., 
http://www.iccwbo.org/advocacy-codes-and-rules/areas-of-work/arbitration-and-adr/ (last visited 
Apr. 3, 2016). 
 70. Neumeyer, supra note 56. 
 71. Id. 
 72. Id. 
 73. Id. 
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arbitration awards than there are court judgments.74  Typically, the main way 
for arbitration to be upheld is if parties agree to the binding nature of 
arbitration at any time before the arbitration occurs.75  Yet many disputes 
involving patents are not derived from a pre-existing relationship.76 
VI.  GENE PATENTING 
The human genome consists of twenty-three pairs of chromosomes 
within the nucleus of all our cells, with an estimated 30,000 genes 
comprising the genome.77  A genome is an organism’s makeup of DNA, 
which contains the complete instructions needed to create and direct the 
activities of the organism.78  DNA molecules are large polymers that encode 
hereditary information that can be passed from generation to generation.79  
By using an RNA intermediate, the information in DNA is used to specify 
the amino acid sequence of proteins.80  DNA is made up of four nitrogenous 
bases that include adenine (A), thymine (T), cytosine (C), and guanine (G).81  
In double-stranded DNA, there is complementary base pairing, where A 
pairs with T by forming two hydrogen bonds, and C pairs with G by forming 
three hydrogen bonds.82  The nucleotide sequence of DNA is copied into 
ribonucleic acid, or RNA, which is then converted in a linear sequence of 
amino acids that creates a protein.83  RNA is a polynucleotide that is 
different from DNA in that it contains only one strand, a different sugar-
ribose instead of deoxyribose, and a fourth base called uracil (U) instead of 
thymine.84 
The two steps involving our body’s production of proteins include 
transcription (which copies information of a DNA sequence into RNA) and 
translation (which converts the RNA sequence into the amino acid sequence 
of a polypeptide).85  Messenger RNA (mRNA) travels from the nucleus to 
 
 74. Id. 
 75. See United Steelworkers v. Warrior & Gulf Navigation Co., 363 U.S. 574, 582 (1960). 
 76. Neumeyer, supra note 56. 
 77. Human Genome Project Completion: Frequently Asked Questions, NAT’L HUM. GENOME 
RES. INST., http://www.genome.gov/11006943 (last updated Oct. 30, 2010).  On April 14, 2003, the 
National Human Genome Research Institute (NHGRI), the Department of Energy (DOE) and their 
partners in the International Human Genome Sequencing Consortium announced the successful 
completion of the Human Genome Project.  Id. 
 78. Id. 
 79. PURVES ET AL., supra note 24, at 54. 
 80. Id. 
 81. Id. 
 82. Id. at 218.  
 83. Id. at 220. 
 84. Id. at 236.  
 85. Id.  
10
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the cytoplasm and serves as a template for the synthesis of proteins.86  
Protein-coding genes contain noncoding base sequences, called introns (that 
do not code for amino acids) that are interspersed with the coding regions, 
called exons (that do code for amino acids).87  There are transcripts of the 
introns in the primary transcript of RNA (pre-mRNA), but when the mRNA 
leaves the nucleus of the cell, the introns have been removed and the exons 
are spliced together.88 
A much smaller DNA library, that may include only the genes 
transcribed for a specific tissue, can be made from complementary DNA, or 
cDNA.89  cDNA is produced by extracting mRNA from a tissue and then 
allowing it to hybridize with a molecule called oligo dT (which consists of a 
string of thymine residues).90  The oligo dT then serves as a primer, and by 
using mRNA as a template, is able to synthesize DNA from RNA (making a 
strand of cDNA that is complementary to the RNA strand, which contains 
only the exons, as noted above).91  Complementary DNA is a good starting 
point for the cloning of eukaryotic genes and is especially useful for cloning 
genes that are expressed at low levels.92  If the amino acid sequence of a 
protein is known, organic chemistry can be applied to create the DNA that 
codes for the specific protein by figuring out an appropriate base sequence.93 
If a mutation occurs in a nucleotide sequence, it can result in a harmless 
alteration, but if it changes the amino acid that is produced, it can cause 
disease.94 Because synthetic DNA can be created in any desired sequence, 
DNA can also be manipulated to create specific mutations, and scientists can 
then determine how the mutant DNA is expressed in the host cell.95  
Scientists can also extract DNA from cells using lab methods and they are 
able to isolate segments of DNA (which can be a particular gene, or part of a 
gene).96  Genetic testing has led to medical breakthroughs.97 
 
 86. Id.  
 87. Id. at 285. 
 88. Id.  
 89. Id. at 325. 
 90. Id. 
 91. Id.  
 92. Id.  
 93. Id. at 325-26. 
 94. Id. at 347. 
 95. Id. at 326. 
 96. Id. at 346-48. 
 97. Id.  For instance, it was determined that the gene responsible for fragile-X syndrome 
contains a repeated triplet, CGG, at a certain point in the promoter region.  Id. at 347.  “[E]xpanding 
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The genetic code is nearly universal, applying to all species on the 
planet, with the exceptions being “few and slight.”98 
Nine percent of women who inherit one mutated allele of the gene 
BRCA1 have a 60% chance of having breast cancer by age fifty and an 82% 
chance of developing it by age seventy.99  Women who inherit the two 
normal alleles of the BRCA1 gene are 2-7%.100 
Myriad found the location of the BRCA1 and BRCA2 genes where 
mutations in these genes can dramatically increase the risk of breast or 
ovarian cancer.101  Before its discovery, scientists did not know which genes 
were associated with those cancers.102  By determining the nucleotide 
sequence, Myriad was able to develop tests that are useful for detecting 
mutations in these genes and assessing the risk of cancer.103  Myriad then 
obtained patents after it discovered the location and sequence.104  When 
Myriad determined that a lab at the University of Pennsylvania was using 
similar testing methods, Myriad sent letters to the university asserting that 
the testing infringed on their patents.105  GDL agreed to stop testing.106  
Myriad also filed patent infringement suits against other entities that 
performed BRCA testing that resulted in settlements in which defendants 
agreed to cease all allegedly infringing activity.107  Years later, Ostrer, filed a 
lawsuit in Myriad seeking a declaration that Myriad’s patents were invalid 
under 35 U.S.C. § 101.108 
Since Myriad found the genes as they occur in nature, the Court, in its 
precedential decision, found that they are not patent eligible.109  However, 
since a lab technician creates something new when cDNA is created, that is 
a different story and the cDNA is patent eligible.110  The Supreme Court has 
left it at that—that genes and the information they encode are not patent 
eligible simply because they have been isolated from the surrounding 
genetic material.111  The Court did not address scenarios such as if a short 
 
triplet repeats have been found in over a dozen other diseased, such as myotonic dystrophy 
(involving repeated CTG triplets) and Huntington’s disease (in which CAG is repeated).”  Id.  
 98. Id. at 240. 
 99. Id. at 354.  
 100. Ass’n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107, 2120 (2013). 
 101. Id. at 2112. 
 102. Id. 
 103. Id. at 2112-13 
 104. Id. at 2113. 
 105. Id. at 2114. 
 106. Id. 
 107. Id. 
 108. Id. 
 109. Id. at 2117. 
 110. Id. 
 111. Id. at 2120. 
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strain of DNA does not have intervening introns to be removed when the 
cDNA segment is created, which would mean that it would be 
indistinguishable in form from natural DNA.112 
Before Myriad’s discovery of the BRCA1 and BRCA2 genes, scientists 
knew that heredity played a role in establishing a woman’s risk of 
developing breast and ovarian cancer, but they did not know which genes 
were associated with those cancers.113  Myriad identified the exact location 
of the BRCA1 and BRCA2 genes on chromosomes 17 and 13.114  
Knowledge of the location of the genes allowed Myriad to determine their 
nucleotide sequence.115  That information enabled Myriad to develop tests to 
detect mutations in these genes.116  Before this decision was made, Myriad’s 
diagnostic tools were expensive for the average uninsured consumer, costing 
thousands of dollars (typically around $3,000).117  After the decision, testing 
became available by other companies, and the cost of the testing decreased 
and became more affordable.118  Although the decision can be looked at as 
allowing more access to medical tools for the public, it can also be looked at 
as giving less incentive to companies to develop new testing methods since 
there appears to be less protection for those who make initial discoveries 
(and less of a financial reward for these monopolistic companies). 
Further, in another recent case, Ariosa Diagnostics v. Sequenom, 
plaintiff Ariosa, formerly known as Aria Diagnostics, sought a declaration 
that its non-invasive prenatal test, the Harmony test, using cell-free fetal 
DNA circulating in the blood of a pregnant woman did not directly infringe 
or contribute to the infringement of U.S. Patent No. 6,258,540 (the 540 
patent), that was licensed by the defendant, Sequenom.119  Sequenom was 
the exclusive licensee of the 540 patent.120  The 540 patent related to 
prenatal detection methods that were “performed on a maternal serum or 
plasma sample [taken] from a pregnant female,” and the methods used 
detected the presence of a paternally inherited nucleic acid of fetal origin in 
 
 112. Id. at 2107-20.  
 113. Id. at 2112. 
 114. Id. 
 115. Id. 
 116. Id. 
 117. Maryn Wilcoxson, Note, A Lesson Learned from Myriad: The Affordable Care Act As 
Both an Incentive and an Alternative for Invalidating Stem Cell Patents, 48 IND. L. REV. 723, 735 
(2015). 
 118. Id. 
 119. Ariosa Diagnostics v. Sequenom, 19 F.Supp. 3d 938, 940-41 (N.D. Cal. 2013) aff’d, 788 
F.3d 1371 (Fed. Cir. 2015).  
 120. Id. at 941. 
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the sample.121  The invention was innovative because it enabled non-invasive 
prenatal diagnosis, which included sex determination, blood typing, and 
detection of pre-eclampsia in the mother.122  Other pre-natal diagnostic DNA 
tests, such as chorionic villus sampling, utilized invasive procedures that 
involved risks to the mother and the pregnancy.123  The noninvasive testing 
was made possible after the discovery by two doctors that cell-free fatal 
DNA (cffDNA) is detectable in maternal serum or plasma sample, and that 
the detection rate was “much higher using the serum or plasma than using 
the nucleated blood cell DNA extracted from a comparable volume of whole 
blood.”124 
 Ariosa argued that the claims of the ‘540 patent were not centered on 
patent eligible subject matter because the patent merely added routine and 
conventional activity to a natural phenomenon.125  Yet Sequenom believed 
that the methods were patentable since they were novel uses of a natural 
phenomenon.126  However, in order to have a patent on a process that: 
[F]ocuses upon the use of a natural law, a natural phenomenon, or 
an abstract idea[,] [the invention] must contain other elements or a 
combination of elements, sometimes referred to as an “inventive 
concept,” sufficient to ensure that the patent in practice amounts to 
significantly more than a patent upon the natural law, natural 
phenomenon, or abstract idea itself.127 
The District Court ultimately held that the only inventive concept 
contained in the patent is the discovery of cffDNA, which is not 
patentable.”128  Accordingly, the district court granted Ariosa’s motion for 
summary judgment.129  The court believed that the effect of issuing the 
patent would be to preempt all know methods of detecting cffDNA at that 
time.130  The Federal Circuit later upheld the District Court’s decision.131  
According to the Federal Circuit’s reasoning, the claims in that case are 
method claims, which are generally eligible subject matter, yet the court 
declined to rule that the claim contained an inventive concept that was 
inventive enough to transform the naturally occurring phenomenon into a 
 
 121. Id. 
 122. Id. 
 123. Id. at 941.  
 124. Id. 
 125. Id. at 948. 
 126. Id. 
 127. Id. at 948-49 (citing Prometheus, 132 S.Ct. at 1294); see also Parker v. Flook, 437 U.S. 
584, 594 (1978). 
 128. Ariosa Diagnostics v. Sequenom, Inc., 19 F.Supp. 3d 938, 950-51 (N.D. Cal. 2013) aff’d, 
788 F.3d 1371 (Fed. Cir. 2015). 
 129. Id. at 954. 
 130. Id. at 949. 
 131. Ariosa Diagnostics v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015). 
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patent-eligible invention.132  The court indicated that “patent claims should 
not prevent the use of the basic building blocks of technology-abstract 
ideals, naturally occurring phenomena, and natural laws.”133 
Further, last year the Supreme Court decided another case regarding 
patents, Alice Corp. Pty. v. CLS Bank Int’l, that was centered on patents that 
disclosed a computer-implemented scheme for mitigating “settlement risk” 
by using a third-party intermediary.134  The Supreme Court affirmed the 
decision of the United States Court of Appeals for the Federal Circuit.135  
Relying heavily on the Mayo136 decision, the court determined that the 
patents were based on an abstract idea and that “the mere recitation of a 
generic computer cannot transform a patent-ineligible abstract idea into a 
patent-eligible invention.”137 
VII.  CASE LAW - COLLATERAL ESTOPPEL 
In Blonder-Tongue Laboratories v. University of Illinois Foundation, 
the Supreme Court held that in patent infringement suits, a patentee (a holder 
of a patent) is estopped from asserting the validity of a patent that has been 
declared invalid in a prior suit in federal court against a different defendant, 
unless the patentee demonstrates that he did not have full and fair 
opportunity, procedurally, substantively, and evidentially, to litigate the 
validity of his patent in the prior suit.138  The case centered on the 
patentability of antennas.139  In a prior infringement action, a patent held by 
 
 132. Id. at 1376.  The court noted: 
Because the claims at issue are directed to naturally occurring phenomena, we turn to the 
second step of Mayo’s framework.  In the second step, we examine the elements of the 
claim to determine whether the claim contains an inventive concept sufficient to 
“transform” the claimed naturally occurring phenomenon into a patent-eligible 
application.  We conclude that the practice of the method claims does not result in an 
inventive concept that transforms the natural phenomenon of cffDNA into a patentable 
invention. 
Id. at 1376-77.  See also Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289, 1294 
(2012); Parker v. Flook, 437 U.S. 584, 591 (1978) (“The process itself, not merely the mathematical 
algorithm, must be new and useful.”). 
 133. Ariosa Diagnostics v. Sequenom, Inc., 788 F.3d 1371, 1379 (Fed. Cir. 2015). 
 134. Alice Corp. Pty. v. CLS Bank Int’l, 134 S.Ct. 2347, 2351 (2014). 
 135. Id. at 2360. 
 136. According to Mayo, conventional activity cannot transform an unpatentable law of nature 
into patent-eligible application of such law.  Mayo Collaborative Servs. v. Prometheus Labs., 132 
S.Ct. 1289 (2014). 
 137. Alice,134 S.Ct. at 2351. 
 138. Blonder-Tongue Labs., v. Univ. of Ill. Found., 402 U.S. 313 (1971). 
 139. Id. 
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the University of Illinois Foundation was determined to be invalid.140  
Thereafter, the Foundation brought an action against Blonder-Tongue 
Laboratories, the defendant, in the district court for alleged infringement of 
the same patent.141  The District Court allowed the Foundation to bring its 
infringement action against Blonder-Tongue and the Foundation 
prevailed.142  The court of appeals affirmed the district court’s judgment in 
favor of the Foundation.143  Blonder-Tongue then appealed to the United 
States Supreme Court, arguing that non-mutual collateral estoppel precluded 
the Foundation from bringing the subsequent action because the patent’s 
invalidity was already established in an earlier action.144  The court held that 
once a patent has been declared invalid via judicial inquiry, a collateral 
estoppel barrier is created against further litigation involving the patent, 
unless the patentee can establish that he did not have a fair chance to litigate 
the validity of his patent in an earlier case.145 
In Lear, Inc. v. Adkins, 146 an inventor brought the action against one of 
the patent’s licensees for allegedly breaching the patent licensing 
agreement.147  The Supreme Court ruled that there was no estoppel of the 
licensee in his efforts to assert that the patent was invalid.148  Furthermore, 
the Court ruled that the licensee was validly able to decline royalty payments 
that had accrued if the licensee could prove the invalidity of the patent.149  
The inventor responded by asserting that Lear should be forced to pay the 
royalties according to the agreement, regardless of the underlying patent’s 
validity.150  The Court in Lear overturned the doctrine of licensee 
estoppel,151 holding that public interest considerations require that licensee 
be free to challenge the validity of possibly spurious patents under which 
they are licensed.152  The court held that “the equities of the licensor do not 
weigh very heavily when they are balanced against the important public 
interest in permitting full and free competition in the use of ideas which are 
in reality a part of the public domain.”153  It reasoned that licensees may 
often be the only individuals with enough economic incentive to challenge 
 
 140. Id. at 349-50. 
 141. Id. at 314. 
 142. Id. at 314-15. 
 143. Id. at 315. 
 144. Id. at 326. 
 145. Id. at 333. 
 146. Lear, Inc. v. Adkins, 395 U.S. 653 (1969). 
 147. Id. 
 148. Id. 
 149. Id. 
 150. Id. at 656. 
 151. See Automatic Radio Mfg. Co. v. Hazeltine Research, 339 U.S. 827 (1950).  
 152. Lear, 395 U.S. at 653. 
 153. Id. at 656. 
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the patentability of an inventor’s discovery, and “if they are muzzled, the 
public may continually be required to pay tribute to would-be       
monopolists . . . .”154  The Court addressed that “the technical requirements 
of contract doctrine must give way [to] the demands of the public interest in 
the typical situation involving the negotiation of a license after a patent has 
[been] issued.”155 
In its reasoning, the Supreme Court acknowledged that a conflict exists 
between the demands of contract law, forbidding a purchaser to “repudiate 
his promises simply because he later becomes dissatisfied with the bargain,” 
and the policy that requires “all ideas in general circulation be dedicated to 
the common good unless they are protected by a valid patent.”156  Thus, the 
conclusion recognizes that the equities of the licensor under contract law 
were less important than the interests of the public to grant freedom in 
sharing ideas and promoting competition.157  Basing its reasoning on the 
strong federal policy in favor of the free use of ideas, the Court held that the 
licensee, Lear, must be permitted not to pay patent royalties to Adkins if it 
could prove that the patent for the gyroscope was invalid, despite the 
agreement not to challenge the license.158 
In contrast, typically an arbitration award cannot be used to assert 
collateral estoppel in a subsequent lawsuit unless there is privity among the 
parties.159  Privity requires an identity of interests, or a relationship that is 
close enough to validate applying the doctrine.160  In situations where two 
parties are in privity, the parties must have had their interests adequately 
represented in order to be bound by such proceeding.161  Thus, if there is no 
agreement to the contrary, issues decided by arbitration are able to be re-
litigated.162  For instance, in Vandenberg v. Superior Court, the California 
Supreme Court indicated that it was “compelled to conclude that a private 
arbitration award, even if judicially confirmed, can have no collateral 
estoppel effect in favor of third persons . . .”163  However, there are also 
 
 154. Id. at 670. 
 155. Id. at 670-71. 
 156. Id. at 668. 
 157. Id. at 670. 
 158. Id. at 674. 
 159. See James M. Westerlind, The Preclusive Effects of Arbitration Awards, ARENT FOX (Aug. 
20, 2010), http://www.arentfox.com/sites/default/files/Mealeys-Article-
PreclusiveEffectofArbAwards.pdf. 
 160. Citizens for Open Access v. Seadrift Ass’n, 60 Cal. App. 4th 1053, 1070 (1998). 
 161. Trujillo v. County of Santa Clara, 775 F.2d 1359, 1367 (9th Cir. 1985).  
 162. See Vandenberg v. Superior Court, 21 Cal. 4th 815 (1999). 
 163. Id. at 834. 
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exceptions.  In Santor v. Superior Court, the First District Court of Appeals 
held that since a corporation, a party in the arbitration, could act exclusively 
through its agents and employees, the findings of the arbitration could be 
used by third party agents/employees in establishing a basis for collateral 
estoppel claims.164  The court held, “[s]ince a corporation may act only 
through its agents, a finding that the corporation was liable . . . can be 
pleaded by petitioners as res judicata in the subsequent action against 
them.”165  The court applied the rules set forth in Bernard v. Bank of 
America, and concluded that the issues decided in the arbitration proceeding 
with respect to the first, second and third causes of action, were identical 
with the ones that were pursued in the action against petitioners.166 
Additionally, in Kelly v. Vons Cos., the court pointed out that issues 
determined in arbitrations by a tribunal can be given collateral estoppel 
effect when: 
(1) [T]he issue is identical to that decided in the former proceeding; 
(2) the issue was actually litigated and (3) necessarily decided; (4) 
the doctrine is asserted against a party to the former action or one 
who was in privity with such a party; and (5) the former decision is 
final and was made on the merits.167 
The party can be granted collateral estoppel for that issue if the 
arbitration was not an informal proceeding, but rather contained the 
formality and safeguards that a formal action may have—the court there 
determined that the action “had the elements of an adjudicatory 
procedure.”168  Thus, in addition to the five elements listed above, to rule in 
favor of applying collateral estoppel, a party needs to also establish that the 
prior arbitrations had the following elements of an adjudicatory procedure: 
an impartial officer, a qualified officer, a formal recording of testimony 
under oath, cross-examinations, motions, discovery, and a written statement 
of the decision.169  Consequently, there are exceptions to the rule to not 
allow the assertion of collateral estoppel by a third party based on a prior 
arbitration award, but typically collateral estoppel will not apply unless the 
above listed criteria are met.170 
On March 20, 2012, the United States Supreme Court ruled in Mayo 
Collaborative Services v. Prometheus Laboratories171 that a process patent, 
 
 164. Sartor v. Superior Court, 136 Cal. App. 3d 322 (1982); Paloma Ramirez & Patrick 
Mendes, The Use of Collateral Estoppel After Arbitration, TYSON & MENDES (Oct. 16, 2014), 
http://www.tysonmendes.com/blog-collateral-estoppel/. 
 165. Sartor, 136 Cal. App. 3d at 328. 
 166. Id.  
 167. Kelly v. Vons Cos., 67 Cal. App. 4th 1329, 1331 (1998). 
 168. Id. at 1336; Ramirez & Mendes, supra note 164. 
 169. Ramirez & Mendes, supra note 164. 
 170. See Part VII, supra, and accompanying notes.  
 171. Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289, 1304 (2012). 
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which Prometheus Laboratories had obtained for correlations between blood 
test results and patient health in determining an appropriate dosage of a 
specific medication for the patient, is not eligible for a patent because the 
correlation is a law of nature.172  The Court reasoned, “methods for making 
such determinations were well known in the art, this step simply tells doctors 
to engage in well-understood, routine, conventional activity previously 
engaged in by scientists in the field.”173  The decision has been criticized for 
conflating two separate patent law concepts (patent eligibility under Section 
101 of the Patent Act and obviousness for patentability under Section 
103),174 and potentially invalidating many patents relating to the 
biotechnology, medical diagnostics and pharmaceutical industries.175 
However, the American Medical Association (AMA) praised the decision 
for invalidating patents that would have hampered the ability of physicians 
to provide quality patient care.176 
VIII.  ADDITIONAL DEVELOPMENTS REGARDING PATENT DISPUTES 
President Ronald Reagan was responsible for enacting laws, which were 
to become 35 U.S.C. § 294 in 1983.177  This section empowered the federal 
courts’ enforcement of arbitration agreements, regardless of the agreement’s 
timing being prior to or following the patent disputes.178  Furthermore, the 
Patent Trial and Appeal Board (PTAB) was given credibility as a judicial 
power over issued patents by the America Invents Act of 2011.179  The 
 
 172. Id. at 1297 (noting a process reciting a law of nature is also not considered patentable 
unless the process has features that “provide practical assurance that the process is more than a 
drafting effort designed to monopolize the law of nature itself”).  See also Ariosa Diagnostics v. 
Sequenom, Inc., 19 F. Supp. 3d 938, 947 (N.D. Cal. 2013). 
 173. Mayo, 132 S. Ct. at 1291. 
 174. 35 U.S.C. §§ 101, 103 (2015). 
 175. Gene Quinn, Killing Industry: The Supreme Court Blows Mayo v. Prometheus, 
IPWATCHDOG, (Mar. 20, 2012), http://www.ipwatchdog.com/2012/03/20/supreme-court-mayo-v-
prometheus/id=22920/. 
 176. Charlie Stiernberg, Supreme Court Diagnotsitc Process Claims as Unpatentable Laws of 
Nature, HARV. J. L. & TECH. (Mar. 20, 2012), http://jolt.law.harvard.edu/digest/patent/mayo-
collaborative-servs-v-prometheus-labs-inc.  
 177. See Charles W. Shifley, Goodbye Patent Arbitration?, BANNERWITCOFF.COM (Fall 2014), 
http://bannerwitcoff.com/_docs/library/articles/Corporate%20Counsel%20Special%20IP%20Section
.Shifley.Goodbye%20Patent%20Arbitration.pdf 
 178. Charles W. Shifley, Goodbye Patent Arbitration?, CORP. COUNS., (Oct.13, 2014), 
http://www.corpcounsel.com/id=1202672879326/Goodbye-
PatentArbitration?slreturn=20150007231928. 
 179. Id. 
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PTAB does not discern infringement issues.180  In contrast, the PTAB merely 
judges the patentability of inventions.181  However, it cannot judge on claims 
of patent infringement.182  Since late 2012, there have been 1,100 petitions 
filed to the PTAB for the review of patents.183  Astoundingly, January 
through June of 2014 saw filings increase to 125% more than the same that 
were filed in 2013 as a whole.184  PTAB proceedings benefit the goals of 
patent challengers because the PTAB has denied patentability to many 
claims.185  Due to the recent increase in PTAB proceedings, arbitration may 
have another need to be revived.  
A.  The Way Arbitration Works 
Typically, when the disputing parties’ determination has been made to 
arbitrate as opposed to litigate, the parties must give notice and agree to the 
binding nature of arbitration.186  Furthermore, the resulting award of the 
arbitration cannot be enforced unless the Director of the Patent Office has 
been notified and this notice becomes a part of the patent’s prosecution 
record.187  Notwithstanding the undeniable power of the aforementioned 
agreements, the Director still maintains the ability to rule upon the nature of 
invention’s patent and what it claims.188  Thus, the arbitration binds the 
parties, but “the patentability of the invention goes to the public interest in 
having only valid patents in existence.”189 
Section 294 of the Patent Act allows for arbitration clauses in of any 
contractual dispute that relates to patent validity or infringement.190  This 
section usually relates to patent license agreements, but can be broader.191  
Parties can agree to arbitrate either in the contract or after the dispute has 
arisen.192  If they agree to arbitrate after the dispute has arisen, they may 
agree to it in writing.193  Interestingly, Section 294(c) states that the award 
 
 180. Id. 
 181. Id. 
 182. Id. 
 183. Id. 
 184. Id. 
 185. Id.  
 186. See David Allgeyer, Arbitrating the Patent Case Part IX: Statutory Provisions, ADR 
COMMUNITY (Oct. 28, 2014), https://community.adr.org/docs/DOC-1392. 
 187. Id. 
 188. Id.  
 189. Id.  
 190. Id.; 35 U.S.C. § 294 (2012). 
 191. Allgeyer, supra note 186. 
 192. Id. 
 193. Id.  
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binds only the parties.194  This could potentially benefit the person who holds 
the patent.  However, there is a lack of clarity on whether an invalidity 
finding will bind the patent holder if he later sues another party to bolster 
attempts to capture royalties.  With arbitration, the answer is typically no, it 
would not.195  However, this ambiguity stems from the fact that 294(c) 
addresses that arbitration binds the parties to the dispute.196 Even though 
another party will have “notice” once it is recorded, the decision of 
invalidity is not binding over later disputes.197  However, a licensor can have 
a provision in the arbitration clause that the award states what is owed in 
royalties without giving specific reasons.198  In that case, a third party would 
not be able to readily determine the rationale for the award or the invalidity 
determined.  Arbitration is a great alternative due to the fact that when jury 
trials determine the outcome of a patent case, verdicts may seem to lack a 
logical basis and jurors and judges may not understand the technology 
involved or background of significant issues.199 
B.  Mediation 
Mediation can also be “especially helpful in patent licensing and 
infringement cases in which the parties can explore mergers, cross-licensing, 
royalty rate negotiations, etc.”200  It makes sense to utilize mediation with 
patent disputes since there can be more winners in the equation.201  
Moreover, the parties agree on an outcome that “can avoid the risk of the 
judge or jury giving an unreasonable award.”202  It is possible that if a patent 
dispute is delayed due to litigation, a better product may be on the market 
after hard earned dollars are spent and the litigation is still stagnant and 
underway.  Time is a crucial factor with patent licensing disputes, especially 
in fields such as the pharmaceutical industry.203 
 
 194. Id.; 35 U.S.C. § 294(c) (1982). 
 195. Allgeyer, supra note 186. 
 196. Id.; See 35 U.S.C. § 294(c) (1982). 
 197. Allgeyer, supra note 186.  
 198. Sayler, supra note 27. 
 199. Metcalf, supra note 10, at 385. 
 200. Id at 386 (citing W. Levenson Dean, Let’s Make a Deal: Negotiating Resolution of 
Intellectual Property Disputes Through Mandatory Mediation at the Federal Circuit, 6 JOHN 
MARSHALL REV. INTELL. PROP. L. 369 (2007)). 
 201. Metcalf, supra note 10, at 386. 
 202. Id. 
 203. Id. 
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The parties “can control how long the proceedings last and set deadlines 
to ensure that no time is wasted.”204  Other notable aspects favoring 
mediation is that it can induce settlement by helping to expedite the 
negotiations processes earlier.205  Mediation further protects the parties’ 
confidentiality interests.206  Mediation uniquely enables the parties in dispute 
to “customize and fortify confidentiality in order to protect trade secrets and 
other valuable information.”207  Litigation’s counterpart to this flexible 
confidentiality is a protective order.208  This type of order is issued in the 
efforts to protect certain information from other parties.209  Parties in 
mediation can make the entirety of the proceedings confidential, including 
the terms of the settlement, and the communications are typically protected 
and not admissible into evidence in other proceedings.210  It is clear that the 
normal background of patent licensing disputes is a contract.  Since the 
adversarial nature of mediation is not nearly as strong as that of litigation, 
the business relationship can sometimes be repaired.211  In cases that relate to 
technology, the mediators are handpicked for their knowledge and 
experience of the disputed field of law.212 
IX.  INTERNATIONAL ARBITRATION OF PATENT DISPUTES 
Some of arbitration’s strong suits are that it calls for shorter 
proceedings, lower costs, and knowledgeable arbitrators.213  Arbitration is 
beneficial to parties in patent disputes as the parties typically choose 
arbitrators that are experts with special technological or scientific expertise 
in the required field.214  Because of this expert knowledge, the arbitrators can 
more easily understand the nuanced subjects that become the heart of 
disputes.215  Furthermore, this type of dispute resolution can help avoid 
confusion and delays.216  Additionally, because arbitrators can readily 
understand the pending issues, expert witnesses may not be needed and 
money can further be saved.217  If an arbitrator has a depth of knowledge 
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within the field, he will be more likely to adhere to industry standards and to 
refrain from excessive punishment.218  However, with litigation, it may be 
harder for members of the general public to determine the standards within 
that field and how far one may have deviated from the norm.  Thus, it makes 
more sense for someone who knows the industry well to determine if one 
has done wrong to another and what a reasonable award for the discretion 
would be.219  Also, a panel of arbitrators with their combined expertise could 
cover several different relevant areas to the dispute.220 
Additionally, the Federal Circuit reviews patent claims from the cistrict 
court under the de novo standard of review.221  This means that, once a 
patent dispute reaches the Federal Circuit Court, the parties then must retry 
the case from the beginning.222  Therefore, not only can litigation 
exponentially increase costs of dispute resolution, but it can also allow for 
confidentiality to be lost in its lengthy proceedings.223 
A.  International Concerns 
If a patent owner has a patent that is being infringed upon in several 
countries, it is imperative that the owner brings an enforcement action in all 
of those countries.224  However, complications do arise in situations where 
nations differ on their intellectual property philosophies.225  For instance, in 
contrast to the U.S. statute, the European Patent Convention does not 
explicitly state which inventions are patent eligible, but instead excludes 
specific categories.226  Some countries allow patents to protect a broader 
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spectrum of rights, whereas some countries remain narrower in their 
views.227 Consolidation several proceedings into a single proceeding is ideal 
because the multi-national claims can get very complex because they can be 
subject to the judgment of several jurisdictions. 
International arbitration through the World Intellectual Property 
Organization, also known as WIPO,228 has added benefits when utilized for 
international parties.229  WIPO is a United Nations (UN) agency that 
oversees treaties involving copyright, patent, and trademark laws and was 
created in 1967.230  It has registered international patents and also developed 
international patent legislation.231  WIPO is a self-governing body that has 
drafted rules and created the Arbitration and Mediation Center to provide a 
center that focuses on IP dispute resolution.232  This system offers parties an 
effective alternative to international litigation.233  With 180 members, it 
offers a solution when parties shy away from settling these types of disputes 
in the courts of another country due to concerns over partiality.234  This 
offers a somewhat simple solution when juxtaposed with the complexities 
and messiness that can result in several multi-national litigants that bring 
suits that are governed by various conflicting laws.235 
Looking at the way ADR can be implemented reveals how, for instance, 
experienced arbitrators who have a substantive background in the disputed 
topics can better serve the parties at dispute than most judges could.236  In 
addition, this type of experienced referee decreases expenditures and 
“improves the quality of the decision” by supporting the decision with the 
arbitrator’s own expertise.237  IP law’s sensitivity to timely dispute resolution 
is unparalleled across multiple fields of law.  Undoubtedly, there may be 
exceptions to certain patent cases where litigation may be necessary. 
However, many current issues surrounding patent litigation can be solved by 
the use of mediation or arbitration.  These modes of dispute resolution 
provide parties with decisions that are better founded and more quickly 
decided so that the public more readily has access to the wealth of 
knowledge necessary for rapid technological innovation. 
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X.  PROPOSED SOLUTION 
There should be an increased use of arbitration in resolving licensing 
disputes.  Patent disputes, specifically those stemming from licensing 
agreements, should go through arbitration because it enables parties to take 
advantage of arbitration’s tendency to promote confidentiality, 
specialization, finality, and cost-savings.238  Arbitration can be a voluntary 
process where the parties agree to have a neutral third-party.  In addition, the 
disputing parties would ideally choose a highly qualified professional who 
has knowledge of the nuanced field that gives rise to the dispute.239  
Additionally, the informal process of arbitration offers flexibility, high pace, 
and a finality that draws from arbitration’s binding nature.240  All of these 
traits of arbitration support the goals of facilitating business and 
innovation.241 
In contrast, litigation entails an inventor filing a complaint and alleging 
breach of licensing contract or infringement of patent.  The defendant would 
claim that the patents are invalid and therefore, there is no infringement.  
This process would call for discovery and possible waiting times between 
motions of past an entire year.  The final judgment at trial can be continued 
and delayed to a point where time has been wasted and both parties grow 
stale.  In addition, the opportunity for an appeal on the final verdict could 
extend the case even further until the “company’s IP rights and product lines 
have been in legal limbo” for years.242  If the dispute is resolved according to 
arbitration rules, “[b]ecause the arbitrator understands patent law, she is able 
to efficiently review and understand a large volume of testimony and 
evidence, including complex technical data,”243 and can do so quickly to 
potentially get a product more readily available on the market. 
Other countries have even considered eliminating human gene 
patents.244  Those who oppose gene patenting argue that costs of healthcare 
would decrease and progress in research would increase.245  However, those 
parties who support gene patenting bolster their argument with the idea that 
the patent system provides the required incentives that support innovations 
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within the biotechnology field.246  Due to their profound impact on human 
life and disease-prevention, gene patents present an issue that needs 
modification.  The complex processes of licensing and royalties can serve to 
deter genetic research.  Arbitration is a tool that can streamline this process 
and provide better results. 
XI.  HOW THIS PROPOSAL COULD IMPACT PUBLIC WELFARE 
On November 3, 2014, the Children’s Hospital of Eastern Ontario, 
Canada brought suit against the University of Utah regarding patents held by 
the university for genes associated with Long QT Syndrome.247  The 
syndrome causes abnormal, life-threatening heart rhythms and children that 
inherit certain genetic mutations die suddenly from the condition unless they 
receive the necessary genetic testing and therapy.248  The University of Utah 
first obtained Long QT gene patents in 1997, and then initially licensed its 
rights to a U.S. company that did not develop any genetic testing, but did 
stop other entities from studying the genes, including suing a U.S. laboratory 
that was offering a Long QT test to the public.249  Due to gene patent 
disputes, there was no genetic testing offered for the disorder in the United 
States for two years.250  As a result, doctors could not test patients that they 
believed may have the genetic mutations and, consequently, could not 
prescribe the effective therapies.251  A case in point is that of 10-year old 
Abigail, an American citizen, who succumbed to Long QT Syndrome and 
died undiagnosed.252  Notwithstanding Myriad’s holding that a naturally 
occurring genetic code cannot be patented, there are several American 
universities and companies that have maintained foreign patents on the same 
genes for which they hold a patent in the United States.253  PGx Health, an 
American organization acting with the help of the University of Utah, 
acquired licensing to Long QT.254  Through these acquired licenses, PGx 
halted Canadian medical center’s efforts to administer testing to patients.255  
As a result, the cost of the test skyrocketed to an unreasonably high rate of 
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over $4,000 per patient.256  This cost was a result of international postage 
rates, and is extremely unreasonable considering that local Canadian 
hospitals were slated to charge a grand total of $1,500 per tested patient.257  
It is clearly unethical when the corporate concern of increased income 
generation takes precedence over the international availability of life-saving 
testing. 
A.  How Could a System Be Put Into Place? 
In her article, Kourtney Baltzer proposes that a clearinghouse could be 
established for monitoring and enforcement of licensing deals, with a 
potential alternative dispute resolution system that could include mediation 
and arbitration.258  This system would be tailored to the clearinghouse’s 
granted biotech patents.259  She explains how this would be attractive to 
patent licensees and patent holders, because of its relative cost-effectiveness 
and risk-averseness in comparison to litigation.260  Baltzer further advocates 
the suggestion by specifying that the clearinghouse’s license agreements 
would maintain a clause requiring that all disputes related to the license must 
be resolved through the clearinghouse’s established ADR methods.261  This 
system would ensure that the parties’ expectations regarding future dispute 
resolution are settled on at least the forum and the methodology.262  This not 
only streamlines the process but it creates a security blanket for the parties 
involved, because they know the forum is fair.  Systems similar to Baltzer’s 
proposed alternative dispute resolution clearinghouse could have a profound 
positive consequence on the future of our patents—especially since it would 
prevent companies from losing years of research to litigation. 
B.  Discussion of Potential Objections 
While it is possible that requiring arbitration and confidentiality in 
licensing agreements would be harmful to consumers, it is unlikely.  One 
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problem, however, is that arbitration clauses may be difficult to enforce.  If a 
clearinghouse was utilized to grant licenses, it may pose several problems. 
Objections could possibly be focused on arbitration’s pitfalls.  One of 
these pitfalls is the limited nature of discovery under the arbitrator’s 
orders.263  This limitation denies the parties the multitude of evidence that 
would have otherwise been available to the parties in the pre-trial stages of 
litigation.264  With the complexity that sometimes surrounds these disputes, a 
lack of evidence could prove to be detrimental to a party’s claims.265  
Additionally, although parties to arbitration are supposed to be bound by 
their agreement to arbitrate, there is no definitive answer to the question of 
how extensively the agreement can be enforced.266  For example, will the 
decision be binding in future court proceeding or even those of the 
USPTO?267  It is unclear where the results of litigation and the results of 
arbitration intersect. 
XI.  CONCLUSION 
Patents on genes are ready and able to disrupt innovation and 
technological advancement, “as innovators may find it daunting to obtain 
licenses from all of the many different patent holders of genes that can be 
simultaneously screened.”268  Although Myriad269 made some headway in 
preventing patents on naturally occurring genetic material, labs may still 
decide not to develop a test on a disease due to licensing issues with patents, 
and there is confusion stemming from that precedential decision that seemed 
to cast blurred lines.  The complexities that may arise from the Court’s 
unclear reasoning can decrease a patient’s ability to access critical genetic 
testing.  Since litigation can take years, and because there are less hostile 
ways of solving licensing disputes, a more widely used system of arbitration 
should be put into place.270  Even though the future is unclear, it seems that 
the Supreme Court will allow certain systems of DNA inventions to be 
patented, though it is not likely to grant any patents for individual genes. 271  
Although the innovations addressed in Myriad and Ariosa made significant 
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contributions to the medical field, the inventions at stake were still not 
patentable.272  The pivotal point of patentability will likely depend on 
“methods that more clearly reflect the art of inventions rather than the labor 
of discovery.”273  Perhaps the difficulties with recent Supreme Court 
decisions such as Myriad hint at the fact that lines to be drawn are not so 
clear.  For instance, would one be able to simply make a silent mutation in 
the cDNA to avoid infringing on a patent?274  Perhaps cases need to be 
decided on a case-by-case basis, which seems to fit perfectly with 
arbitration.  Arbitration may prove to allay inventors’ fears of subjecting 
their inventions to the risks of being invalidated, exposed, or negatively 
publicized.275  It may also allow the licensee a quicker chance to get their 
product on the market and available to those in need.  Since arbitrations are 
quicker, more cost-effective, and do not need to reveal specific 
determinations, it may provide for the sensitivities of each party’s needs.  
This allows for companies to take advantage of arbitration decisions that are 
in their favor—without the need to disclose the decision to competitors, and 
the patent holders do not have to face public disclosure of the decisions that 
were made.  Additionally, different companies may alter their invention in a 
number of ways so that the arbitrators may not reach the same decision 
based on the differences in their alterations.  The affect of arbitration would 
thereupon allow companies to make different modifications to the product, 
which would be made possible by the use of arbitration.  Also, the arbitrator 
finds the patent is invalid and the licensee does not have to pay royalties, the 
licensee would not be concerned with whether or not competitors pay 
royalties.  However, even if competitors do pay royalties, the previous 
licensee will gain be a competitive advantage. 
In conclusion, it is surprising how few arbitrations resolve disputes 
related to patents.276  Internationally, the number of patent disputes that are 
submitted to arbitration are merely below one thousand.277  With the benefits 
of arbitration and the hazy Supreme Court decisions that implicate our 
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genetic code, it seems to be an excellent means of resolution that should be 
utilized more in the future.  It would be wise for parties to include arbitration 
agreements in their licensing agreements and would have benefits for both 
parties.  It is hard to predict what the future has in store and which human 
diseases may be prevented.  Although lines need to be more neatly 
demarcated, and mediation may prove to be a special tool for solving related 
disputes as they arise, it is clear that science is reaching new highs and 
technology will meet new bars as it progresses.  However, keeping 
innovation barriers at a minimum278 is significant for an ever-evolving world 
where litigation can halt progress and risk the loss of medical treatment and 
the lives of those in need of care. 
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